Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 20/20 | 0.54 |
| ▸ | MC3R | P41968 | 8/20 | 0.54 |
| ▸ | MC5R | P33032 | 4/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.54 |
| ▸ | MC1R | Q01726 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4603038 | 0.91 | MC4R (0.51) | MC4RMC3RMC5RKCNH2MC1R | |
| SCHEMBL4613397 | 0.91 | MC4R (0.61) | MC4RMC3RMC5RKCNH2MC1R | |
| SCHEMBL4601228 | 0.84 | MC4R (0.55) | MC4RMC3RMC5RKCNH2MC1R | |
| SCHEMBL4612769 | 0.84 | MC4R (0.69) | MC4RMC3RMC5RKCNH2MC1R | |
| SCHEMBL4602267 | 0.80 | MC4R (0.68) | MC4RMC3RMC5RKCNH2MC1R | |
| SCHEMBL4634019 | 0.80 | MC4R (0.50) | MC4RMC3RMC5RKCNH2MC1R | |
| SCHEMBL4940362 | 0.79 | MC4R (0.60) | MC4RMC3RMC5RKCNH2MC1R | |
| SCHEMBL14028098 | 0.78 | MC4R (0.46) | MC4RMC3RMC5RKCNH2MC1R | |
| SCHEMBL29327382 | 0.78 | MC4R (0.46) | MC4RMC3RMC5RKCNH2MC1R | |
| SCHEMBL29327394 | 0.78 | DPP4 (0.51) | MC4RMC3RMC5RKCNH2MC1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024108198-A2 | METHODS OF TREATING OBESITY WITH AN MC4R AGONIST | RHYTHM PHARMACEUTICALS, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| US-20080269233-A1 | Piperidinoyl-Pyrrolidine and Piperidinoyl-Piperidine Compounds | ANDREWS MARK DAVID | 2008-10-30 | — | — | US | disclosed |
| EP-1912968-A1 | PIPERIDINOYL-PYRROLIDINE AND PIPERIDINOYL-PIPERIDINE COMPOUNDS | Pfizer Limited (GB) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007015162-A1 | PIPERIDINOYL-PYRROLIDINE AND PIPERIDINOYL-PIPERIDINE COMPOUNDS | PFIZER LIMITED (GB) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269233-A1 | Piperidinoyl-Pyrrolidine and Piperidinoyl-Piperidine Compounds | GPR4, GPR119, PRLHR | MC4R 4/4885MC3R 86/4885MC5R 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.